Vasopressin should be used with great caution for the treatment of hypotension in septic shock, according to results from an international research team published today in the online open access journal Critical Care. Their experiments - conducted in pigs - show it can significantly reduce blood flow to vital organs.
The peptide hormone vasopressin is being developed as a new therapy for the hemodynamic support of septic shock and vasodilatory shock due to systemic inflammatory response syndrome.
Previously, the compound has been shown to increase blood pressure in septic shock that fails to respond to catecholamines. However, the safety of vasopressin treatment in humans with septic shock is yet to be proven. Now, researchers in Iceland, Switzerland, and the US, have tested the effects of vasopressin on pancreatic, renal, and hepatic perfusion in pigs and discovered that the compound causes severe disturbances in blood flow in these organs.
Dr Vladimir Krejci of the Department of Anesthesiology, Washington University School of Medicine, in St. Louis, Missouri, and colleagues investigated the effects of vasopressin on pigs divided into in four groups. Group S (sepsis) and group SV (sepsis/vasopressin) were exposed to fecal peritonitis, while Group C and Group V were non-septic controls. The team measured regional blood flow in the hepatic and renal arteries, the portal vein, and the celiac trunk by means of ultrasonic transit time flowmetry.
They found that in septic shock, vasopressin markedly decreased blood flow (by 58%) in the portal vein within an hour, and even after three hours the reduction stood at 45%. Flow was unchanged in the hepatic artery and increased in the celiac trunk, but was unchanged in the liver. Microcirculatory blood flow in the pancreas also fell considerably and, to a lesser extent, in the kidney. The investigation also revealed that increased urine output does not necessarily reflect increased renal blood flow and so may not be a useful indicator of the effects of a particular treatment.
Article: Vasopressin in septic shock
Vladimir Krejci, Luzius B Hiltebrand, Stephan M Jakob, Jukka Takala and Gisli H Sigurdsson
Critical Care (in press)
During the embargo, article available at:
After the embargo, article available at journal website:
Article citation and URL available on request at firstname.lastname@example.org on the day of publication
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Critical Care is a high quality, peer-reviewed, international clinical medical journal. Critical Care aims to improve the care of critically ill patients by acquiring, discussing, distributing, and promoting evidence-based information relevant to intensivists. The journal is edited by Prof Jean-Louis Vincent (Belgium) and has an Impact Factor of 3.12
BioMed Central (www.biomedcentral) is an independent online publishing house committed to providing immediate access without charge to the peer-reviewed biological and medical research it publishes. This commitment is based on the view that open access to research is essential to the rapid and efficient communication of science.